For research use only
| Cat No. | ABC-TC5520 |
| Product Type | Pulmonary Cells |
| Cell Type | Fibroblast |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Idiopathic Pulmonary Fibrosis |
| Storage | Liquid Nitrogen |
Diseased Human Lung Fibroblasts, Idiopathic Pulmonary Fibrosis support fibrosis mechanisms, ECM remodeling, and antifibrotic drug screening research.
Diseased Human Lung Fibroblasts, Idiopathic Pulmonary Fibrosis (lung fibroblasts) are derived from the lung tissue of patients with idiopathic pulmonary fibrosis (IPF). These fibroblasts are human in originThe cells are human in origin, straight from. These cells are long spindle-shaped or star-shaped, with typical fibroblast morphology, and embedded within and interacting with the extracellular matrix. They proliferate in an anchorage-dependent manner. Their karyotype is generally normal but can sometimes show instability due to disease progression. They show abnormal expression of fibrotic markers like alpha-smooth muscle actin (α-SMA) and fibronectin, detectable by immunostaining or PCR. In the pathological process of IPF, lung fibroblasts play a pivotal role by proliferating abnormally and secreting excessive amounts of extracellular matrix components, such as collagen type I/III and fibronectin, which ultimately lead to lung tissue fibrosis. These human lung fibroblasts serve as a disease-relevant in vitro model for studying fibrotic mechanisms, fibroblast–lung microenvironment interactions, and for evaluating anti-fibrotic therapeutic strategies.
| Product Code | DHLF-IPF |
| Species | Human |
| Cat.No | ABC-TC5520 |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | Fibroblast |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Idiopathic Pulmonary Fibrosis |
| Storage | Liquid Nitrogen |
| Product Type | Pulmonary Cells |
| Key Features | -Backed by AcceGen advanced technology |
Diseased Human Lung Fibroblasts, Idiopathic Pulmonary Fibrosis can be utilized to screen anti-fibrotic compounds or evaluate the efficacy and mechanisms of existing drugs, such as nintedanib or pirfenidone. Furthermore, comparative studies between IPF fibroblasts and healthy lung fibroblasts may help identify disease-specific biomarkers and uncover novel therapeutic targets.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).